📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis. (2023)

First Author: Smith SL

Attributed to: Maximising Therapeutic Utility for Rheumatoid Arthritis using genetic and genomic tissue responses to stratify medicines. funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1136/ard-2022-222519

PubMed Identifier: 36810200

Publication URI: http://europepmc.org/abstract/MED/36810200

Type: Journal Article/Review

Volume: 82

Parent Publication: Annals of the rheumatic diseases

Issue: 5

ISSN: 0003-4967